- cafead Apr 25, 2024 at 11:42: AM
via Alkermes has commenced the Vibrance-1 Phase II clinical trial to evaluate ALKS 2680 in patients with narcolepsy type 1 (NT1).
ALKS 2680 is an investigational oral orexin 2 receptor (OX2R) agonist intended as a once-daily treatment for the chronic neurological disorder known for causing excessive daytime sleepiness.
article source
ALKS 2680 is an investigational oral orexin 2 receptor (OX2R) agonist intended as a once-daily treatment for the chronic neurological disorder known for causing excessive daytime sleepiness.
article source